A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab

• Verfasst von: Schalk, Gesa [VerfasserIn]
• Verfasst von: Kirschfink, Michael [VerfasserIn]
• Verfasst von: Wehling, Cyrill [VerfasserIn]
• Verfasst von: Gastoldi, Sara [VerfasserIn]
• Verfasst von: Bergmann, Carsten [VerfasserIn]
• Verfasst von: Hoppe, Bernd [VerfasserIn]
• Verfasst von: Weber, Lutz T. [VerfasserIn]
• Titel: A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab
• Verf.angabe: Gesa Schalk, Michael Kirschfink, Cyrill Wehling, Sara Gastoldi, Carsten Bergmann, Bernd Hoppe, Lutz T. Weber
• E-Jahr: 2015
• Jahr: 10 March 2015
• Umfang: 4 S.
• Fussnoten: Gesehen am 17.06.2020
• Titel Quelle: Enthalten in: Pediatric nephrology
• Ort Quelle: Berlin : Springer, 1987
• Jahr Quelle: 2015
• Band/Heft Quelle: 30(2015), 6, Seite 1039-1042
• ISSN Quelle: 1432-198X
• DOI: doi:10.1007/s00467-015-3078-6
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1700745247

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy characterized by uncontrolled activation of the alternative complement pathway with consecutive generation of the terminal complement complex. Mortality is increased, particularly in the first year of the disease. Therapeutic options include plasma therapy and terminal complement blockade using the anti-C5 monoclonal antibody eculizumab. Eculizumab prevents activation of the terminal sequence of the complement cascade and formation of the potentially lytic terminal complement complex (C5b-9).